These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 23391723)

  • 1. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
    Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
    J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
    Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
    Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model.
    Drabsch Y; He S; Zhang L; Snaar-Jagalska BE; ten Dijke P
    Breast Cancer Res; 2013 Nov; 15(6):R106. PubMed ID: 24196484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition.
    Zuo ZQ; Chen KG; Yu XY; Zhao G; Shen S; Cao ZT; Luo YL; Wang YC; Wang J
    Biomaterials; 2016 Mar; 82():48-59. PubMed ID: 26751819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells.
    Jia D; Li L; Andrew S; Allan D; Li X; Lee J; Ji G; Yao Z; Gadde S; Figeys D; Wang L
    Cell Death Dis; 2017 Jul; 8(7):e2932. PubMed ID: 28703802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.
    Perez R; Schally AV; Vidaurre I; Rincon R; Block NL; Rick FG
    Oncotarget; 2012 Sep; 3(9):988-97. PubMed ID: 22941871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
    Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
    Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell.
    Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y
    Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
    Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
    PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
    Liu P; Kumar IS; Brown S; Kannappan V; Tawari PE; Tang JZ; Jiang W; Armesilla AL; Darling JL; Wang W
    Br J Cancer; 2013 Oct; 109(7):1876-85. PubMed ID: 24008666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
    Bouquet F; Pal A; Pilones KA; Demaria S; Hann B; Akhurst RJ; Babb JS; Lonning SM; DeWyngaert JK; Formenti SC; Barcellos-Hoff MH
    Clin Cancer Res; 2011 Nov; 17(21):6754-65. PubMed ID: 22028490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
    Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
    Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
    He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
    Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
    Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
    Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
    Litzenburger BC; Creighton CJ; Tsimelzon A; Chan BT; Hilsenbeck SG; Wang T; Carboni JM; Gottardis MM; Huang F; Chang JC; Lewis MT; Rimawi MF; Lee AV
    Clin Cancer Res; 2011 Apr; 17(8):2314-27. PubMed ID: 21177763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.